Skip to main content
. Author manuscript; available in PMC: 2017 Jun 5.
Published in final edited form as: Psychopharmacology (Berl). 2013 May 5;229(1):199–208. doi: 10.1007/s00213-013-3099-4

Figure 2.

Figure 2

Figure 2

(A) Potentiated startle magnitudes for the Acquisition Phase before treatment. *p < .05 vs. CS−. (B) Potentiated startle magnitude to the CS+ during Late Acquisition and Early, Mid and Late Extinction phase by Treatment Group. *p < .05 vs. placebo. # p < .05 vs. Early Extinction phase responding within group. (C) Potentiated startle magnitudes to the CS+ during Early extinction depicted in two-trial blocks. *p<0.05, main effect of oxytocin. Data are depicted as mean±SEM difference scores in peak startle magnitude during CS+ or CS− trials compared to noise alone trials.